Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.

Article Details

Citation
Copy to clipboard

Schimke K, Davis TM

Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.

Curr Opin Investig Drugs. 2007 Apr;8(4):338-44.

PubMed ID
17458185 [ View in PubMed
]
Abstract

Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.

DrugBank Data that Cites this Article

Drugs